Skip to main content
Journal cover image

Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.

Publication ,  Journal Article
Yang, C-FJ; Gulack, BC; Gu, L; Speicher, PJ; Wang, X; Harpole, DH; Onaitis, MW; D'Amico, TA; Berry, MF; Hartwig, MG
Published in: J Thorac Cardiovasc Surg
December 2015

OBJECTIVE: Radiotherapy is commonly used in induction regimens for patients with non-small cell lung cancer with operable mediastinal nodal disease, although evidence has not shown a benefit over induction chemotherapy alone. We compared outcomes between induction chemotherapy and induction chemoradiation using the National Cancer Data Base. METHODS: Induction radiation use and survival of patients who underwent lobectomy or pneumonectomy after induction chemotherapy for clinical T1-3N2M0 non-small cell lung cancer in the National Cancer Data Base from 2003 to 2006 were assessed using logistic regression, general linear regression, Kaplan-Meier, and Cox proportional hazard analysis. RESULTS: Of 1362 patients who met study criteria, 834 (61%) underwent induction chemoradiation and 528 (39%) underwent induction chemotherapy. Lobectomy was performed in 82% of patients (n = 1111), and pneumonectomy was performed in 18% of patients (n = 251). Pneumonectomy was performed more often after induction chemoradiation than after induction chemotherapy (20% vs 16%, P = .04). Downstaging from N2 to N0/N1 was more common with induction chemoradiation compared with induction chemotherapy (58% vs 46%, P < .01), but 5-year survival of patients receiving induction chemoradiation and patients receiving induction chemotherapy was similar in unadjusted analysis (41% vs 41%, P = .41). In multivariable analysis, the addition of radiation to induction chemotherapy also was not associated with a survival benefit (hazard ratio, 1.03; 95% confidence interval, 0.89-1.18; P = .73). CONCLUSIONS: Induction chemoradiation is used in the majority of patients with non-small cell lung cancer with N2 disease who undergo induction therapy before surgical resection, but it is not associated with improved survival compared with induction chemotherapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

December 2015

Volume

150

Issue

6

Start / End Page

1484 / 1492

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Respiratory System
  • Pneumonectomy
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Induction Chemotherapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yang, C.-F., Gulack, B. C., Gu, L., Speicher, P. J., Wang, X., Harpole, D. H., … Hartwig, M. G. (2015). Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. J Thorac Cardiovasc Surg, 150(6), 1484–1492. https://doi.org/10.1016/j.jtcvs.2015.06.062
Yang, Chi-Fu Jeffrey, Brian C. Gulack, Lin Gu, Paul J. Speicher, Xiaofei Wang, David H. Harpole, Mark W. Onaitis, Thomas A. D’Amico, Mark F. Berry, and Matthew G. Hartwig. “Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.J Thorac Cardiovasc Surg 150, no. 6 (December 2015): 1484–92. https://doi.org/10.1016/j.jtcvs.2015.06.062.
Yang C-FJ, Gulack BC, Gu L, Speicher PJ, Wang X, Harpole DH, et al. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Dec;150(6):1484–92.
Yang, Chi-Fu Jeffrey, et al. “Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer.J Thorac Cardiovasc Surg, vol. 150, no. 6, Dec. 2015, pp. 1484–92. Pubmed, doi:10.1016/j.jtcvs.2015.06.062.
Yang C-FJ, Gulack BC, Gu L, Speicher PJ, Wang X, Harpole DH, Onaitis MW, D’Amico TA, Berry MF, Hartwig MG. Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Dec;150(6):1484–1492.
Journal cover image

Published In

J Thorac Cardiovasc Surg

DOI

EISSN

1097-685X

Publication Date

December 2015

Volume

150

Issue

6

Start / End Page

1484 / 1492

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Rate
  • Respiratory System
  • Pneumonectomy
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Induction Chemotherapy